thought call
thought commerci perform good revenu
ep surprisingli overshadow loom uncertainti
humira eu biosimilar eros curv visibl ou humira expect
manag helpfulfor come vs prior
discount thu far also dramat expect vs
previous given recent experi eu biosimilar adopt
discuss recent symposium see takeaway generic/biosimilar
symposium wouldnt surpris see ou humira take anoth leg
inde forecast q/q y/i vs consensu
q/q y/i discount major unprotect market potenti reach
high view today call may eas apprehens near term
remain wari humira outlook think share could see pressur
come month biosimilar launch continu progress price discount
negoti across europ recogn potenti
near-term win horizon see could improv sentiment think
share perform larg tie humira franchis given perceiv
pipelin unlik suffici off-set futur eros lower price
target vs prior reflect higher initi discount anticip
grow uncertainti humira competit posit maintain equal weight
near-term pipelin catalyst expect sentiment larg root
humira perform point sever upcom regulatory/clin catalyst
submiss upadacitinib ra remain track potenti launch
expect risankizumab launch also decis venclexta aml
also expect ye decemb pdufa phase bellini data mm
model chang given result adjust revenu forecast
respect prior also adjust opex
estim adjust ep vs
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
larg behind us due settlement
less concern futur
franchis pipelin beyond core
product interest like success
unsur enough make revenu
come introduct humira biosimilar
pipelin success multipl asset indic
would drive revenu thu share price upsid
lessen impact humira biosimilar could also
wors expect impact humira biosimilar
entrant competit prior amgevita
failur pipelin asset could also hamper long-term
price target updat price target valu use
discount cash flow analysi assum wacc vs prior impli
intrins valu per share vs prior
million except per share itemspriorcurrentpriorcurrenthumira non-oper incom ep barclay abbvi inc
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
